Unmet Medical Needs

CAVD has no therapeutic medications,
Aortic Valve Replacement(AVR) is the only option.


Current surgical CAVD treatments include SAVR (Surgical Aortic Valve Replacement), the traditional open-chest aortic valve replacement surgery, and TAVR (Transcatheter Aortic Valve Replacement), a minimally-invasive procedure whereby a catheter is inserted through the leg and into the heart to replace the faulty valve. However, these treatment options carry high risk of death or various other complications. Moreover, given that the average lifetime of a replaced artificial valve is only 10 years, repeated replacement procedures are inevitable, further increasing medical expenses.


21.4M global patients, expected to reach 26.0M by 2040.

Global CAVD Patients : 21.4M

*Sources : Circulation. 2020;141:1670–1680

The prevalence of CAVD increases significantly with age.

Prevalence of Aortic Sclerosis per Mean Age

  • The early stages of CAVD are termed aortic sclerosis.
  • Analytical conclusions of data from 19 research papers (Total 43,204 patients):
  • From age 50, an increasing prevalence of 2% every year
    (Prevalence: 54 years old 9% -> 81 years old 42%)
  • The prevalence of the disease increases 5-fold over a span of 30 years.

*Sources : J Am Coll Cardiol. 2014 Jul 1;63(25 Pt A):2852-61